Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small- cell lung cancer

Moutafi, M.K. (Myrto K.); Molero, M. (Magdalena); Martínez-Morilla, S. (Sandra); Baena, J. (Javier); Vathiotis, I.A. (Ioannis A.); Gavrielatou, N. (Niki); Castro-Labrador, L. (Laura); Ruiz-de-Garibay, G. (Gorka); Adradas, V. (Vera); Orive-Mauleón, D. (Daniel); Valencia, K. (Karmele); Calvo-González, A. (Alfonso); Montuenga-Badia, L.M. (Luis M.); Ponce-Aix, S. (S.); Schalper, K.A. (Kurt A.); Herbst, R.S. (Roy S.); Paz-Ares, L. (Luis); Rimm, D.L. (David L.); Zugazagoitia, J. (Jon)

Palabras clave :

Biomarkers, tumor
Immunotherapy
Lung neoplasms
Programmed cell death 1 receptor
Tumor microenvironment

Fecha de publicación :

2022

Editorial :

BMJ

ISSN :

2051-1426

Nota:

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license

Cita:

Moutafi, M.K. (Myrto K.); Molero, M. (Magdalena); Martínez-Morilla, S. (Sandra); et al. "Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small- cell lung cancer". Journal for immunotherapy of cancer. 10 (8), 2022, e004757

Resumen

Most patients with advanced non-small-cell lung cancer (NSCLC) fail to derive significant benefit from programmed cell death protein-1 (PD-1) axis blockade, and new biomarkers of response are needed. In this study, we aimed to discover and validate spatially resolved protein markers associated with sensitivity to PD-1 axis inhibition in NSCLC.

URI :

https://hdl.handle.net/10171/64953

DOI:

10.1136/jitc-2022-004757

Aparece en las colecciones:

DA - CIMA - Tumores sólidos y biomarcadores- Biomarcadores - Artículos de revista
DA - CUN - Anatomía patológica - Artículos de revista

Ficheros en este ítem: